Detalhe da pesquisa
1.
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10349): 369-379, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908570
2.
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Clin Exp Rheumatol
; 41(11): 2286-2297, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404160
3.
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
Ann Rheum Dis
; 81(11): 1515-1523, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788492
4.
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Ann Rheum Dis
; 79(12): 1600-1607, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32963047
5.
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).
Eur Respir J
; 52(6)2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30337444
6.
Upadacitinib: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(1): e13688, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984057
7.
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
Clin Transl Sci
; 17(2): e13733, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344875
8.
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Rheumatol Ther
; 11(3): 737-753, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683479
9.
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial.
ACR Open Rheumatol
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747163
10.
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
Rheumatol Ther
; 10(1): 275-292, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243812
11.
Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2.
Rheumatol Ther
; 10(4): 887-899, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191738
12.
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Arthritis Res Ther
; 25(1): 172, 2023 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37723577
13.
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
RMD Open
; 8(2)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896281
14.
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir Med
; 9(5): 522-532, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676590
15.
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Arthritis Care Res (Hoboken)
; 64(6): 925-9, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22275160
16.
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.
Arthritis Rheum
; 59(5): 746-753, 2008 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18438908
17.
Therapeutics of Wegener's granulomatosis.
Nat Clin Pract Rheumatol
; 2(4): 192-200, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16932685
18.
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
Am J Med
; 118(12): 1416, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16378799
19.
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
J Cardiovasc Pharmacol
; 41(6): 830-7, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12775959